NovoCure (NVCR) said late Tuesday the US Food and Drug Administration has approved its Optune Lua device to treat adults with metastatic non-small cell lung cancer.
The approval is for the simultaneous use of Optune Lua with PD-1/PD-L1 inhibitors or docetaxel in lung cancer patients who have progressed on or after platinum-based chemotherapy, the company said.
Optune Lua is a device that creates alternating electric fields known as tumor treating fields, which are delivered via wearable arrays to kill cancer cells, NovoCure said.
NovoCure shares jumped nearly 24% in recent after-hours activity.
Price: 22.01, Change: +4.23, Percent Change: +23.79
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.